共 155 条
[1]
Fonner VA(2016)Effectiveness and safety of oral HIV preexposure prophylaxis for all populations AIDS 3012 1973-1983
[2]
Dalglish SL(2017)High levels of adherence to a rectal microbicide gel and to oral pre-exposure prophylaxis (PrEP) achieved in MTN-017 among men who have sex with men (MSM) and transgender women PLoS One 127 e0181607-257
[3]
Kennedy CE(2016)Pharmacokinetic/pharmacodynamic investigation of single-dose oral maraviroc in the context of HIV-1 pre-exposure prophylaxis J Acquir Immune Defic Syndr 733 252-s382
[4]
Baggaley R(2016)PrEP in Europe—expectations, opportunities and barriers J Int AIDS Soc 197 Suppl 6 21103-371
[5]
O’Reilly KR(2015)Translating PrEP effectiveness into public health impact: key considerations for decision-makers on cost-effectiveness, price, regulatory issues, distributive justice and advocacy for access J Int AIDS Soc 184 Suppl 3 19973-158
[6]
Koechlin FM(2016)PrEP implementation in the Asia-Pacific region: opportunities, implementation and barriers J Int AIDS Soc 197 21119-1177
[7]
Carballo-Dieguez A(2017)Awareness, willingness, and use of pre-exposure prophylaxis among men who have sex with men in Washington, DC and Miami-Dade County, FL: national HIV behavioral surveillance, 2011 and 2014 J Acquir Immune Defic Syndr 75 Suppl 3 S375-1103
[8]
Balan IC(2017)Impact of insurance coverage on utilization of pre-exposure prophylaxis for HIV prevention PLoS One 125 e0178737-372
[9]
Brown W(2006)Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment PharmacoEconomics 244 355-834
[10]
Giguere R(2004)Review of guidelines for good practice in decision-analytic modelling in health technology assessment Health Technol Assess 836 1-811